Canine Heartworm, Clinical Presentation and Treatment
World Small Animal Veterinary Association World Congress Proceedings, 2003
A. Eslami *; J. Ashrafi**; B. Meshgi*
*Department of Parasitology, Faculty of Veterinary Medicine, Tehran University ** Department of Pathology, Faculty of Veterinary Medicine
Tehran, Iran

Objectives

To study the prevalence, clinical signs and treatment of Dirofilaria immitis.

Materials & Methods

A total of 198 guard dogs and household dogs from Tabriz northeast of Iran were examined parasitologocally and clinically for heartworm disease. Twelve of infected dogs were treated with melarsomine (Rhon Merieux) at 2.5 mg/kg b.w. and ivermectin at 5µg/kg b.w. and supportive treatments whenever necessary.

Results

Thirty dogs harbored D.immitis of which 4 were amicrofilaraemic. According to the severity of clinical signs 3 groups with no obvious clinical signs (class1, 13 dogs) with moderate clinical signs (class2, 8 dogs) and with severe clinical signs (class3, 9 dogs, 5 microfilaraemic and 4 amicrofilaraemic) were identified in dogs with heartworm disease. Eleven out of twelve dogs selected for treatment were successfully treated but one died post treatment due to sever dirofilariosis and pulmonary thromboembolism.

Conclusion

Dirofilariosis is enzootic in Tabriz and produce subclinical and clinical signs. No relation exists between the number of circulating microfilariae and the severity of the disease. About 50% of severe cases were among amicrofilaraemic dogs. Thus occult dirofilariosis are likely associated with the more sever clinical signs. Melarsomine and ivermectin can be used successfully for treatment of infected dogs.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

A. Eslami
Department of Parasitology, Faculty of Veterinary Medicine
Tehran University


MAIN : Oral Presentations : Canine Heartworm
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27